0R15 8884.0068 1.4156% 0R1E 9171.0 0.0% 0M69 None None% 0R2V 255.5 0.3929% 0QYR 1619.0 0.0% 0QYP 434.5 -0.344% 0RUK None None% 0RYA 1606.0 4.9673% 0RIH 195.2 1.3763% 0RIH 195.2 1.3763% 0R1O 225.5 9877.8761% 0R1O None None% 0QFP None None% 0M2Z 255.0 0.2457% 0VSO 33.3 -6.4738% 0R1I None None% 0QZI 604.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 236.3943 1.5483%
Last update at 2024-12-24T11:54:00Z
Scancell Holdings "well-financed" and continuing to pursue deals
Tue 11 Jul 23, 10:51 AMInvesting in Scancell Holdings (LON:SCLP) three years ago would have delivered you a 146% gain
Thu 06 Jul 23, 08:18 AMHedge funds investors own a significant stake of 44% in Scancell Holdings plc (LON:SCLP)
Mon 17 Oct 22, 12:30 PMHow Many Scancell Holdings plc (LON:SCLP) Shares Do Institutions Own?
Tue 10 May 22, 12:10 PMBeroni Group Announces Appointment of Dr. John Chiplin to Board of Directors
Thu 31 Mar 22, 12:25 PMScancell Holdings (LON:SCLP) Has Debt But No Earnings; Should You Worry?
Fri 28 Jan 22, 06:57 AMWe Think Scancell Holdings (LON:SCLP) Needs To Drive Business Growth Carefully
Tue 31 Mar 20, 10:49 AM| Breakdown | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
| Income before tax | -14.30400M | -3.76800M | -16.80500M | -6.76800M | -6.71401M |
| Minority interest | - | - | - | - | - |
| Net income | -11.93600M | -2.06500M | -15.47700M | -5.50600M | -5.62749M |
| Selling general administrative | 5.02M | 4.79M | 3.35M | 2.12M | 2.58M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 4.75M | - | - | - | - |
| Reconciled depreciation | 0.90M | 0.74M | 0.25M | 0.04M | 0.02M |
| Ebit | -11.63600M | -13.29900M | -8.83400M | -6.78200M | -6.72901M |
| Ebitda | -10.73400M | -7.31200M | -14.90500M | -6.73900M | -6.70795M |
| Depreciation and amortization | 0.90M | 5.99M | -6.07100M | 0.04M | 0.02M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -11.92000M | -13.29900M | -8.83400M | -6.78200M | -6.72901M |
| Other operating expenses | 17.19M | 13.30M | 8.83M | 6.78M | 6.73M |
| Interest expense | 1.22M | 2.88M | 1.65M | 0.01M | 0.00000M |
| Tax provision | -2.36800M | -1.70300M | -1.32800M | -1.26200M | -1.08652M |
| Interest income | 0.28M | 0.00400M | 0.00300M | 0.01M | 0.02M |
| Net interest income | -0.93100M | 2.37M | -7.97100M | 0.01M | 0.02M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -2.36800M | -1.70300M | -1.32800M | -1.26200M | -1.08652M |
| Total revenue | 5.27M | 0.00000M | 0.00000M | 0.00000M | - |
| Total operating expenses | 16.67M | 13.30M | 8.83M | 6.78M | 6.73M |
| Cost of revenue | 0.53M | - | 6.41M | 4.67M | 4.15M |
| Total other income expense net | -2.38400M | 9.53M | -7.97100M | 0.01M | 0.02M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -11.93600M | -2.06500M | -15.47700M | -5.50600M | -5.62749M |
| Net income applicable to common shares | - | -2.06500M | -15.47700M | -5.50600M | -5.62800M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
| Total assets | 30.27M | 49.06M | 8.82M | 10.54M | 10.54M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | - | 3.64M | 3.56M | 2.51M | 2.51M |
| Total liab | 36.50M | 29.57M | 1.17M | 1.21M | 1.21M |
| Total stockholder equity | -6.23300M | 19.48M | 7.65M | 9.34M | 9.34M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | - | 0.34M | 1.20M | -0.12900M | 0.49M |
| Common stock | 0.82M | 0.81M | 0.47M | 0.39M | 0.39M |
| Capital stock | 0.82M | 0.81M | 0.81M | 0.47M | 0.39M |
| Retained earnings | -74.35600M | -47.05400M | -31.57700M | -26.07120M | -26.07120M |
| Other liab | - | 10.10M | 12.03M | - | - |
| Good will | 3.42M | 3.42M | 3.42M | 3.42M | 3.42M |
| Other assets | - | - | - | - | - |
| Cash | 19.92M | 41.11M | 3.58M | 4.56M | 4.56M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 3.28M | 2.29M | 1.17M | 1.21M | 1.21M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -0.38700M | -25.65500M | -3.44600M | -4.43095M | -4.55995M |
| Short term debt | 0.31M | 0.21M | 0.13M | 0.13M | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 19.53M | 15.46M | 0.13M | 0.13M | - |
| Other stockholder equity | 67.30M | 65.72M | 38.76M | 35.52M | 35.52M |
| Property plant equipment | - | 2.74M | 0.97M | 0.20M | 0.06M |
| Total current assets | 24.61M | 44.67M | 5.21M | 7.07M | 7.07M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 14.70M | 16.07M | 4.23M | 5.92M |
| Short term investments | - | - | - | - | - |
| Net receivables | 0.54M | 3.19M | 3.56M | 1.33M | 2.02M |
| Long term debt | 18.48M | 7.01M | 15.18M | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 2.97M | 2.09M | 1.04M | 1.21M | 1.21M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | -0.50186M | -0.50186M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.47M | 0.39M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | - | 3.47M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 5.66M | 4.39M | 3.61M | 3.47M | 3.47M |
| Capital lease obligations | 1.05M | 1.17M | 0.27M | 0.13M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 | 2019-04-30 |
| Investments | 0.08M | -1.26400M | -0.74100M | -0.01300M | 0.01M |
| Change to liabilities | - | 0.05M | 1.05M | -0.16400M | 0.51M |
| Total cashflows from investing activities | - | -1.26400M | -0.74100M | -0.01300M | 0.01M |
| Net borrowings | - | -0.39100M | 23.35M | -0.02700M | -0.02700M |
| Total cash from financing activities | -0.74600M | 46.08M | 3.80M | 1.28M | 1.28M |
| Change to operating activities | - | - | - | - | - |
| Net income | -14.30400M | -16.80500M | -6.76800M | -6.71401M | -6.71401M |
| Change in cash | -8.80500M | 37.53M | -0.98500M | -5.74322M | -5.74322M |
| Begin period cash flow | 28.73M | 3.58M | 4.56M | 10.30M | 10.30M |
| End period cash flow | 19.92M | 41.11M | 3.58M | 4.56M | 4.56M |
| Total cash from operating activities | -8.14000M | -7.80300M | -4.77200M | -7.03295M | -7.03295M |
| Issuance of capital stock | 0.17M | 0.00000M | 24.14M | 3.88M | 1.36M |
| Depreciation | 0.90M | 0.25M | 0.04M | 0.02M | 0.02M |
| Other cashflows from investing activities | - | 0.00400M | 0.00300M | 0.01M | 0.01M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | 0.32M | -0.59700M | 0.31M | -0.58000M |
| Sale purchase of stock | - | - | 24.14M | 3.88M | 1.36M |
| Other cashflows from financing activities | -0.91200M | 21.94M | -0.07700M | -0.08306M | -0.08306M |
| Change to netincome | - | -9.24000M | 6.98M | 0.55M | -1.35600M |
| Capital expenditures | 0.20M | 0.74M | 0.03M | 0.00266M | 0.00266M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.94M | 0.45M | 0.14M | -0.07099M | -0.07099M |
| Stock based compensation | 0.73M | 0.33M | -0.01000M | -0.25401M | -0.25401M |
| Other non cash items | 2.38M | 7.97M | -0.01100M | -0.01500M | -0.01500M |
| Free cash flow | -8.34300M | -8.54700M | -4.79900M | -7.03561M | -7.03561M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SCLP Scancell Hldgs Plc |
0.10 0.91% | 11.10 | - | - | 19.36 | 8.89 | 19.06 | -8.2422 |
| ONT Oxford Nanopore Technologies Ltd |
6.80 5.29% | 135.30 | - | - | 10.88 | 2.75 | 8.77 | -16.7946 |
| GNS Genus PLC |
4.00 0.26% | 1524.00 | 42.59 | 25.71 | 2.08 | 2.46 | 2.31 | 16.39 |
| PRTC PureTech Health plc |
-1.6 1.02% | 154.80 | - | - | 35.55 | 1.04 | 95.87 | -4.5333 |
| AVCT Avacta Group PLC |
1.69 3.52% | 49.69 | - | - | 23.19 | 14.78 | 20.75 | -10.4566 |
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, ovarian, renal, and head and neck cancers; and Modi-2, which targets homocitrullinated cancer antigens. In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
Bellhouse Building, Oxford, United Kingdom, OX4 4GD
| Name | Title | Year Born |
|---|---|---|
| Prof. Lindy Gillian Durrant Ph.D. | Founder, CEO, Chief Scientific Officer & Director | NA |
| Dr. Sally Elizabeth Adams | Chief Devel. Officer & Director | 1961 |
| Mr. Keith Green | Director of Fin. & Admin. and Company Sec. | NA |
| Dr. Samantha Paston Ph.D. | Head of Translational Research | NA |
| Dr. Adrian Parry Ph.D. | Head of Manufacturing | NA |
| Ms. Akua Asare | Head of Quality | NA |
| Mr. Fayaz Master | Head of Clinical Operations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...